Volume 12 Issue 5
Sep.  2021
Turn off MathJax
Article Contents
Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital. Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 674-683. doi: 10.12290/xhyxzz.2021-0554
Citation: Multi-disciplinary Team for Rare Diseases, Peking Union Medical College Hospital. Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(5): 674-683. doi: 10.12290/xhyxzz.2021-0554

Consensus on the Treatment of Adrenocortical Carcinoma with Mitotane(2021)

doi: 10.12290/xhyxzz.2021-0554
Funds:

the Fundamental Research Funds for the Central Universities 3332021003

Youth Research Fund of Peking Union Medical College Hospital pumch201911755

Research Fund of Chinese Research Hospital Association Y2021FH-YWPJ01-106

More Information

    Corresponding author: ZHANG Shuyang  Tel: 86-10-69155810, E-mail: shuyangzhang103@163.com

  • Received Date: 2021-07-25
  • Accepted Date: 2021-08-05
  • Publish Date: 2021-09-30
  • Adrenocortical carcinoma (ACC) is a rare malignant tumor that occurs in the adrenal cortex, and surgery is the first choice for treating ACC. Medical therapy and radiotherapy are adjuvant treatments for patients with unresectable metastasized tumors or incomplete resection. Mitotane is the only adrenergic cytotoxic drug approved by the American Food and Drug Administration and European Medicines Agency for the treatment of ACC by inhibiting mitochondrial respiration, causing mitochondrial membrane dysfunction and inducing endoplasmic reticulum stress, and it reduces the secretory function of ACC cells by inhibiting the function and expression of several enzymes in the adrenocortical steroidogenesis pathway. Mitotane is recommended as the first choice for adjuvant therapy by multiple international guidelines and consensus. During treatment with mitotane, its blood concentration should be maintained between 14 to 20 mg/L, while the related adverse drug reactions and drug-drug interactions should also be monitored. To promote further standardization of the clinical application of mitotane, and to ensure the effectiveness and safety of mitotane, Peking Union Medical College Hospital relied on the multi-disciplinary team for the diagnosis and treatment of rare diseases, organized experts and scholars in related fields to discuss and modify many times, and finally formed this consensus for clinicians' reference.
  • loading
  • [1] Kerkhofs TM, Verhoeven RH, Van JM, et al. Adren-ocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993[J]. Eur J Cancer, 2013, 49: 2579-2586. doi:  10.1016/j.ejca.2013.02.034
    [2] Kebebew E, Reiff E, Duh QY, et al. Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?[J]. World J Surg, 2006, 30: 872-878. doi:  10.1007/s00268-005-0329-x
    [3] Fassnacht M, Libe R, Kroiss M, et al. Adrenocortical carcinoma: a clinician's update[J]. Nat Rev Endocrinol, 2011, 7: 323-335. doi:  10.1038/nrendo.2010.235
    [4] Fassnacht M, Terzolo M, Allolio B, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma[J]. N Engl J Med, 2012, 366: 2189-2197. doi:  10.1056/NEJMoa1200966
    [5] Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment[J]. Curr Opin Investig Drugs, 2005, 6: 386-394.
    [6] Tang Y, Liu Z, Zou Z, et al. Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis[J]. Biomed Res Int, 2018, 2018: 9362108.
    [7] Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage Ⅲ-Ⅳ adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study[J]. Ann Oncol, 2015, 26: 2119-2125. doi:  10.1093/annonc/mdv329
    [8] Amini N, Margonis GA, Kim Y, et al. Curative Resection of Adrenocortical Carcinoma: Rates and Patterns of Postoperative Recurrence[J]. Ann Surg Oncol, 2016, 23: 126-133. doi:  10.1245/s10434-015-4810-y
    [9] Kerkhofs TM, Ettaieb MH, Hermsen IG, et al. Developing treatment for adrenocortical carcinoma[J]. Endocr Related Cancer, 2015, 22: R325-R338. doi:  10.1530/ERC-15-0318
    [10] Hermsen I, Kerkhofs T, Butter C, et al. Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery[J]. Surgery, 2012, 152: 50-56. doi:  10.1016/j.surg.2012.02.005
    [11] Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma[J]. N Engl J Med, 2007, 356: 2372-2380. doi:  10.1056/NEJMoa063360
    [12] Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31: 1476-1490. doi:  10.1016/j.annonc.2020.08.2099
    [13] Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors[J]. Eur J Endocrinol, 2018, 179: G1-G46. doi:  10.1530/EJE-18-0608
    [14] Nelson AF, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2, 2-bis(parachlorophenyl)-1, 1-dichloroethane (DDD or TDE)[J]. Arch Pathol (Chic), 1949, 48: 387-394.
    [15] Bergenstal DM, Hertz RO, Lipsett MB, et al. Chemotherapy of adrenocortical cancer with o, p'DDD[J]. Ann Int Med, 1960, 53: 672-682. doi:  10.7326/0003-4819-53-4-672
    [16] Terzolo M, Ardito A, Zaggia B, et al. Management of adjuvant mitotane therapy following resection of adrenal cancer[J]. Endocrine, 2012, 42: 521-525. doi:  10.1007/s12020-012-9719-7
    [17] Shawa H, Deniz F, Bazerbashi H, et al. Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study[J]. Int J Endocrinol, 2013, 2013: 624962.
    [18] Weigand I, Schreiner J, Röhrig F, et al. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type Ⅱ ferroptosis induction[J]. Cell Death Dis, 2020, 11: 192. doi:  10.1038/s41419-020-2385-4
    [19] Poli G, Guasti D, Rapizzi E, et al. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells[J]. Endocr Relat Cancer, 2013, 20: 537-550. doi:  10.1530/ERC-13-0150
    [20] LaPensee CR, Mann JE, Rainey WE, et al. ATR-101, a Selective and Potent Inhibitor of Acyl-CoA Acyltransferase 1, Induces Apoptosis in H295R Adrenocortical Cells and in the Adrenal Cortex of Dogs[J]. Endocrinology, 2016, 157: 1775-1788. doi:  10.1210/en.2015-2052
    [21] Lin CW, Chang YH, Pu HF. Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells[J]. Toxicology, 2012, 298: 14-23. doi:  10.1016/j.tox.2012.04.007
    [22] Zsippai A, Szabo DR, Tombol Z, et al. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study[J]. Pharmacogenomics, 2012, 13: 1351-1361. doi:  10.2217/pgs.12.116
    [23] Lehmann TP, Wrzesinski T, Jagodzinski PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCIH295R adrenocortical cells[J]. Mol Med Rep, 2013, 7: 893-900. doi:  10.3892/mmr.2012.1244
    [24] Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma[J]. Surgery, 1997, 122: 1212-1218. doi:  10.1016/S0039-6060(97)90229-4
    [25] Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group[J]. World J Surg, 2001, 25: 891-897. doi:  10.1007/s00268-001-0047-y
    [26] Calabrese A, Basile V, Puglisi S, et al. Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence[J]. Eur J Endocrinol, 2019, 180: 387-396. doi:  10.1530/EJE-18-0923
    [27] Puglisi S, Calabrese A, Basile V, et al. Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment[J]. J Clin Med, 2019, 8: 1850. doi:  10.3390/jcm8111850
    [28] Puglisi S, Calabrese A, Basile V, et al. Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma[J]. Cancers (Basel), 2020, 12: 740. doi:  10.3390/cancers12030740
    [29] Gonzalez RJ, Tamm EP, Ng C, et al. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma[J]. Surgery, 2007, 142: 867-875. doi:  10.1016/j.surg.2007.09.006
    [30] Haak HR, Hermans JF, Lentjes EF, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients[J]. Br J Cancer, 1994, 69: 947-951. doi:  10.1038/bjc.1994.183
    [31] Lagana M, Grisanti S, Cosentini D, et al. Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience[J]. Cancers (Basel), 2020, 12: 941. doi:  10.3390/cancers12040941
    [32] Williamson SK, Lew D, Miller GJ, et al. Phase Ⅱ evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study[J]. Cancer, 2000, 88: 1159-1165. doi:  10.1002/(SICI)1097-0142(20000301)88:5<1159::AID-CNCR28>3.0.CO;2-R
    [33] Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o, p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results[J]. Clin Endocrinol (Oxf), 2006, 64: 110-113. doi:  10.1111/j.1365-2265.2005.02403.x
    [34] Mauclere DS, Leboulleux S, Borget I, et al. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up[J]. Eur J Endocrinol, 2012, 166: 261-268. doi:  10.1530/EJE-11-0557
    [35] Terzolo MF, Daffara FF, Zaggia BF, et al. Management of adrenal cancer: a 2013 update[J]. J Endocrinol Invest, 2014, 37: 207-217. doi:  10.1007/s40618-013-0049-2
    [36] Terzolo MB. Adjunctive treatment of adrenocortical carcino-ma[J]. Curr Opin Endocrinol Diabetes Obes, 2008, 15: 221-226. doi:  10.1097/MED.0b013e3282fdf4c0
    [37] Kerkhofs T, Baudin E, Terzolo M, et al. Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma[J]. J Clin Endocrinol Metab, 2013, 98: 4759-4767. doi:  10.1210/jc.2013-2281
    [38] Creemers SG, Hofland LJ, Feelders RA. Management of Adrenal Masses in Children and Adults[M]. Berlin, Germany: Springer International Publishing, 2017: 225-243.
    [39] Vezzosi DA, Do Cao C, Hescot S, et al. Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors[J]. Horm Cancer, 2018, 9: 62-69. doi:  10.1007/s12672-017-0313-6
    [40] Reimondo G, Puglisi S, Zaggia B, et al. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma[J]. Eur J Endocrinol, 2017, 177: 361-367. doi:  10.1530/EJE-17-0452
    [41] Kerkhofs TM, Derijks LF, Ettaieb HF, et al. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma[J]. Ther Drug Monit, 2016, 37: 58-65.
    [42] Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101: 364-389. doi:  10.1210/jc.2015-1710
    [43] Daffara F, De Francia S, Reimondo GF, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly[J]. Endocr Relat Cancer, 2008, 15: 1043-1053. doi:  10.1677/ERC-08-0103
    [44] Baudin E, Pellegriti GF, Bonnay MF, et al. Impact of monitoring plasma 1, 1-dichlorodiphenildichloroethane (o, p'DDD) levels on the treatment of patients with adreno-cortical carcinoma[J]. Cancer, 2001, 92: 1385-1392. doi:  10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2
    [45] Slooten H, Moolenaar A, Seters A, et al. The treatment of adrenocortical carcinoma with o, p'-DDD: prognostic implications of serum level monitoring[J]. Eur J Cancer Clin Oncol, 1984, 20: 47-53. doi:  10.1016/0277-5379(84)90033-6
    [46] Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection[J]. Eur J Endocrinol, 2013, 169: 263-270. doi:  10.1530/EJE-13-0242
    [47] Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity[J]. Eur J Endocrinol, 2011, 164: 621-626. doi:  10.1530/EJE-10-0956
    [48] Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma[J]. Clin Endocrinol (Oxf), 2011, 75: 585-591. doi:  10.1111/j.1365-2265.2011.04214.x
    [49] Greenman Y. Management of dyslipidemia in Cushing's syndrome[J]. Neuroendocrinology, 2010, 92: 91-95. doi:  10.1159/000314294
    [50] Tripto-Shkolnik L, Blumenfeld Z, Bronshtein M, et al. Pregnancy in a Patient With Adrenal Carcinoma Treated With Mitotane: A Case Report and Review of Literature[J]. J Clin Endocrinol Metab, 2013, 98: 443-447. doi:  10.1210/jc.2012-2839
    [51] Corbière P, Ritzel K, Cazabat L, et al. Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma[J]. J Clin Endocrinol Metab, 2015, 100: 4604-4611. doi:  10.1210/jc.2015-2341
    [52] Rodriguez-Galindo C, Krailo MD, Pinto EM, et al. Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol[J]. J Clini Oncol, 2021: 39: 2463-2473.
    [53] Liu X, Fu Q, Tang Y, et al. A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring[J]. Medicine (Baltimore), 2020, 99: e22620. doi:  10.1097/MD.0000000000022620
    [54] Russo M, Scollo C, Pellegriti G, et al. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism[J]. Clin Endocrinol (Oxf), 2016, 84: 614-619. doi:  10.1111/cen.12868
    [55] Vikner ME, Krogh J, Daugaard G, et al. Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients[J]. Clin Endocrinol (Oxf), 2021, 94: 141-149. doi:  10.1111/cen.14345
    [56] Tada H, Nohara AF, Kawashiri MF, et al. Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma[J]. J Atheroscler Thromb, 2014, 21: 1326-1329. doi:  10.5551/jat.27557
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(6)

    Article Metrics

    Article views (2730) PDF downloads(1477) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return